Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Increased to Sell at Wall Street Zen

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a note issued to investors on Sunday.

CRNX has been the subject of a number of other reports. JonesTrading cut Crinetics Pharmaceuticals from a "buy" rating to a "hold" rating and set a $85.00 target price for the company. in a research report on Tuesday, July 7th. Oppenheimer reaffirmed a "market perform" rating on shares of Crinetics Pharmaceuticals in a research report on Tuesday, July 7th. Piper Sandler downgraded Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Robert W. Baird increased their price objective on Crinetics Pharmaceuticals from $62.00 to $85.00 and gave the company an "outperform" rating in a report on Tuesday, July 7th. Finally, TD Cowen lowered shares of Crinetics Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $78.27.

Crinetics Pharmaceuticals Stock Down 0.0%

CRNX traded down $0.04 on Friday, reaching $83.58. The company had a trading volume of 7,356,237 shares, compared to its average volume of 6,742,002. Crinetics Pharmaceuticals has a 1 year low of $25.83 and a 1 year high of $83.76. The stock has a market capitalization of $8.81 billion, a PE ratio of -16.29 and a beta of 0.23. The stock has a 50-day moving average price of $40.38 and a 200-day moving average price of $42.57.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The company had revenue of $10.73 million during the quarter, compared to analyst estimates of $8.51 million. During the same quarter in the prior year, the company earned ($1.04) EPS. The business's revenue was up 2873.4% on a year-over-year basis. As a group, analysts expect that Crinetics Pharmaceuticals will post -4.86 earnings per share for the current fiscal year.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the sale, the director directly owned 6,400 shares of the company's stock, valued at approximately $228,288. This trade represents a 51.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of the business's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 19,225 shares in the company, valued at approximately $769,000. The trade was a 13.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Crinetics Pharmaceuticals by 11.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company's stock worth $1,995,000 after acquiring an additional 6,148 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Crinetics Pharmaceuticals by 6.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company's stock valued at $11,658,000 after purchasing an additional 22,305 shares during the period. Strs Ohio purchased a new stake in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $124,000. Invesco Ltd. boosted its holdings in Crinetics Pharmaceuticals by 11.7% in the 2nd quarter. Invesco Ltd. now owns 78,140 shares of the company's stock valued at $2,247,000 after purchasing an additional 8,181 shares in the last quarter. Finally, Sei Investments Co. increased its position in Crinetics Pharmaceuticals by 20.6% during the 2nd quarter. Sei Investments Co. now owns 60,180 shares of the company's stock worth $1,731,000 after purchasing an additional 10,269 shares during the period. Hedge funds and other institutional investors own 98.51% of the company's stock.

Key Stories Impacting Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Crinetics shares have jumped sharply this week, with the acquisition by Vertex Pharmaceuticals likely the main driver of the rally. Why Crinetics Stock Soared 99% This Week
• Positive Sentiment: Options activity spiked as investors bought far more call contracts than usual, signaling bullish trading interest in CRNX.
• Neutral Sentiment: Crinetics was mentioned in an article about expanding its rare-disease focus, which reinforces the company’s long-term strategic theme but does not appear to be an immediate stock-moving catalyst. Why Is Crinetics NASDAQ: CRNX Expanding Rare Disease Focus?
• Neutral Sentiment: Short interest data showed 0 shares reported as short, suggesting no meaningful bearish positioning from that metric, though the data appears unusual and may not be informative.
• Negative Sentiment: Evercore ISI downgraded Crinetics from strong-buy to hold, implying less upside from current valuation. Evercore downgrade coverage
• Negative Sentiment: Citizens JMP also cut CRNX to hold, adding to analyst caution after the stock’s rapid advance. Citizens JMP downgrade coverage
• Negative Sentiment: TD Cowen initiated or reiterated a hold stance, and a shareholder law firm announced an investigation tied to the Vertex sale, both of which could pressure sentiment. Crinetics Pharmaceuticals NASDAQ: CRNX Receives "Hold" Rating from TD Cowen Shareholder Alert Investigation

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.